cannabinoids

As Insys Therapeutics Inc (NASDAQ: INSY) shifts from opioid therapies to cannabinoids and spray technology, one analyst sees an opportunity to buy in. The Rating Janney analyst Yun Zhong assumed coverage with a Buy rating and cut his price target from $16 to $11. The Thesis Insys forecasted at...

The month of August has been hard one for cannabis drug stocks. After Zynerba Pharmaceuticals Inc (NASDAQ: ZYNE) reported a pair of disappointing trial results in its Phase 2 STAR 1 and STOP trials, respectively, the company’s market cap went up in smoke to the tune of a more than 50 percent...

Healthcare has been one of the best performing sectors of the U.S. stock market for years, but in 2015, shares of healthcare stocks have suffered slightly. Many investors began to worry about the impact next year's presidential election might have on the sector. Some candidates have voiced concern...